About: Low level laser therapy as a modality to attenuate cytokine storm at multiple levels, enhance recovery, and reduce the use of ventilators in COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Low level laser therapy as a modality to attenuate cytokine storm at multiple levels, enhance recovery, and reduce the use of ventilators in COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Low level laser therapy as a modality to attenuate cytokine storm at multiple levels, enhance recovery, and reduce the use of ventilators in COVID-19
Creator	Mokmeli, Soheila Vetrici, Mariana
source	Medline; PMC
abstract	The global pandemic COVID-19 is a contagious disease and its mortality rates ranging from 1% to 5% are likely due to acute respiratory distress syndrome (ARDS), and cytokine storm. A significant proportion of patients who require intubation succumb to the disease, despite the availability of ventilators and the best treatment practices. Researchers worldwide are in search of anti-inflammatory medicines in the hope of finding a cure for COVID-19. Low-level laser therapy (LLLT) has strong, anti-inflammatory effects confirmed by meta-analyses, and it may be therapeutic to ARDS. LLLT has been used for pain management, wound healing, and other health conditions by physicians, physiotherapists, and nurses worldwide for decades. In addition, it has been used in veterinary medicine for respiratory tract disease such as pneumonia. Laser light with low-power intensity is applied to the surface of the skin to produce local and systemic effects. Based on the clinical experience, peer-reviewed studies, and solid laboratory data in experimental animal models, LLLT attenuates cytokine storm at multiple levels and reduces the major inflammatory metabolites. LLLT is a safe, effective, low-cost modality without any side-effects that may be combined with conventional treatment of ARDS. We summarize the effects of LLLT on pulmonary inflammation and we provide a protocol for augmenting medical treatment in COVID-19 patients. LLLT combined with conventional medical therapy has the potential to prevent the progression of COVID-19, minimize the length of time needed on a ventilator, enhance the healing process, and shorten recovery time.
has issue date	2020-07-23(xsd:dateTime)
bibo:doi	10.29390/cjrt-2020-015
bibo:pmid	32844112
has license	cc-by-nc
sha1sum (hex)	7e050fe7a3f3a181580459cd2751edb73a702bb2
schema:url	https://doi.org/10.29390/cjrt-2020-015
resource representing a document's title	Low level laser therapy as a modality to attenuate cytokine storm at multiple levels, enhance recovery, and reduce the use of ventilators in COVID-19
has PubMed Central identifier	PMC7428000
has PubMed identifier	32844112
schema:publication	Can J Respir Ther
resource representing a document's body	covid:7e050fe7a3f3a181580459cd2751edb73a702bb2#body_text
is schema:about of	named entity 'recovery' named entity 'Low level laser therapy' named entity 'COVID-19' named entity 'attenuate' named entity 'Low level laser therapy' named entity 'multiple' named entity 'Ther' named entity 'Can' named entity 'DNA fragmentation' named entity 'mast cell degranulation' named entity 'lung' named entity 'clinical trials' named entity 'COVID-19' named entity 'apoptotic pathways' named entity 'mitochondrial' named entity 'macrophages' named entity 'edema' named entity 'alveolar' named entity 'NF-kB' named entity 'meta-analysis' named entity 'infrared laser' named entity 'inflammatory diseases' named entity 'inflammatory diseases' named entity 'severe acute respiratory syndrome' named entity 'genotoxicity' named entity 'fever' named entity 'IL-1β' named entity 'supine position' named entity 'LLLT' named entity 'COVID-19' named entity 'IL-10' named entity 'animal studies' named entity 'IL-10' named entity 'SARS' named entity 'intracellular' named entity 'anti-inflammatory effect' named entity 'blood vessels' named entity 'TNF-a' named entity 'lung tissue' named entity 'metabolites' named entity 'LLLT' named entity 'ovaries' named entity 'laser diode' named entity 'benign tumors' named entity 'respiratory conditions' named entity 'medical treatment' named entity 'ARDS' named entity 'cell culture' named entity 'endorphins' named entity 'infection' named entity 'ACE2' named entity 'photon' named entity 'lymphatic drainage' named entity 'lung' named entity 'sympathomimetics' named entity 'lung' named entity 'end organ damage' named entity 'etiology' named entity 'reactive oxygen species' named entity 'bronchoalveolar lavage' named entity 'glucocorticoid' named entity 'SARS-CoV-2' named entity 'Middle East respiratory syndrome' named entity 'neutrophils' named entity 'intensive care unit' named entity 'infection' named entity 'anti-inflammatory effect' named entity 'neutrophil' named entity 'calcium channels' named entity 'LLLT' named entity 'anti-inflammatory effect' named entity 'neutrophils' named entity 'lungs' named entity 'immune response' named entity 'LLLT' named entity 'lung tissue' named entity 'IL-6' named entity 'inflammatory cytokines' named entity 'collagen' named entity 'anti-inflammatory effect'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software